Valentine Delabie

3 weeks left to register for BioFIT 2022 with the Super Early Bird rate

3 weeks left to register for BioFIT 2022 with the Super Early Bird rate

Don't miss the "Super Early Bird" offer!

Register before Thursday, March 31st and
benefit from preferential rates to connect with 
1,000+ key innovation players involved in Life Sciences

You want to enhance your online & on-site visibility before and during the event 
to boost your business opportunities? Book an equipped stand now! 

Sponsors

Contact

Marine Pentier

✨ Happy New Year from the BioFIT team!

✨ Happy New Year from the BioFIT team!

The BioFIT team wishes you all the best for this new year!

We are more than ready to ensure that 2022 will be rich in opportunities and collaborations, and we are eager to be by your side as we return to an in-person edition of BioFIT.
We look forward to welcoming you to BioFIT 2022 in Strasbourg on November 29th & 30th, 2022,

The BioFIT team

You want to maximise your business development opportunities in 2022? Looking to connect with 1,000+ key international players in the Life Sciences sector? 
Take part in BioFIT partnering event!

As the leading partnering event in Europe, BioFIT provides the ideal environment for academic and industrial actors to:

  • Build partnerships
  • Source innovative and competitive early-stage R&D projects
  • Facilitate the emergence of collaborative projects
  • Increase licensing opportunities
  • Obtain funding and facilitate market access

⏳ Thanks to the Super Early Bird offer, running until the end of March, you can benefit from very preferential rates to join the BioFIT 2022 edition.

The 11th edition of BioFIT will take place on November 29th & 30th, 2022 
in the charming city of Strasbourg!

Register now and book your stand to benefit from the
Super Early Bird offer, valid until March 31st, 2022!

Sponsors

Contact

Marine Pentier

Save the Date for BioFIT 2022

Save the Date for BioFIT 2022

A successful 10th edition for BioFIT

From December 7th to 9th was organised, in a digital format, the 10th edition of BioFIT, the leading European partnering event for early-stage innovation deals and investment rounds in the field of Life Sciences.

This digital experience over 3 days allowed participants to take away new ideas, collaborations, and funding opportunities, all to build the innovations of tomorrow in the Life Sciences sector. This year, BioFIT was organised with MedFIT, the European partnering event for innovation partnerships and investment rounds in the MedTech, Diagnostic and Digital Health sectors.

BioFIT and MedFIT Digital 2021 key numbers:
  • 1,000 delegates
  • 9,000 one-on-one meetings initiated
  • 35 countries represented
  • 22 conferences
  • 100 speakers
  • 70 innovative projects presented during the Pitch Sessions

BioFIT is back in 2022!

We hope to have the pleasure of welcoming you to the 11th edition on November 29th & 30th, 2022 
in the charming city of Strasbourg!

Register now and benefit from the Super Early Bird offer valid until March 31st, 2022!

Sponsors

Contact

Marine Pentier

And the winners of the BioFIT 2021 Pitch Sessions are…

And the winners of the BioFIT 2021 Pitch Sessions are…

Vésale Bioscience, awarded the most innovative start-up

21 start-ups were selected to pitch during the Start-up Slams at BioFIT in different categories such as infectious, 3D-cell culture tools, therapeutics, cancerology/oncology, AI/big data and diagnostics. Vésale Bioscience, a Belgium start-up represented by Philippe Ghem, Chief Commercial Officer, is the winner of the BioFIT 2021 Start-up Slams:

We are very proud to receive this award. It recognises the great work performed by the Vésale Bioscience team and further motivates us to pursue our research into solutions to multidrug-resistant infections, which constitute a major global public health challenge. We are in the middle of a Series A funding round; this prize serves to validate our development choices and our credibility.”

Vésale Bioscience, a biotech company specialising in phage therapy, with a particular focus on research into alternative solutions to antibiotics and the development of treatments for multidrug-resistant infections. The Belgian start-up is developing an effective and reproducible phage therapy approach that offers a personalised solution to the major issue of AntiMicrobial Resistance (AMR).

VALANX Biotech, awarded the most promising technology

19 TTOs, universities, research institutes and companies have been selected to pitch during the BioFIT Collaborative and Licensing Opportunity Presentations in different categories: infectious, inflammation, CNS, research tools and cancerology/oncology. VALANX Biotech, an Austrian project represented by Michael Lukesch, CEO, received the “Most Promising Technology” award:

We are incredibly honoured to receive the BioFIT price. The award is very helpful in communicating to our collaboration partners, customers and investors the quality of the work we do which would not be possible without our gifted and dedicated team.”

VALANX Biotech develops a site-specific protein conjugation platform with the goal to make the struggle of precise, reproducible protein conjugation a thing of the past, for the benefit of our partners, customers, and patients. Our goal is to be the first company to offer up to 10 freely selectable conjugation sites on any expressible protein in excellent yield to give superior product quality. With our conjugation platform in place we have started to develop VLX101 a novel cytokine conjugate with applications in the treatment of autoimmune disease.

An Anses project, awarded as the most innovative in animal health

5 innovative animal health projects have been selected to present for the Animal Health Presentations and showcased their project in front of potential partners and investors. The French organisation Anses, represented by Olivier Bourry, Deputy Head of NRL African Swine Fever, submitted a project which was awarded during the Animal Health Presentations and won the 2021 competition:

This was our first participation in BioFIT and we are honoured that our project was awarded as the most innovative animal health project. BioFIT was a very good opportunity to present our vaccine candidate against African Swine Fever to potential industrial partners. We hope the exchanges initiated during BioFIT will lead to the development of our vaccine and give the pig sector an indispensable tool to fight against this devastating disease that is currently spreading all around the world.”

ANSES (French Agency for Food, Environmental and Occupational Health & Safety) has a network of nine laboratories, located throughout the country, near the related production sectors. The Ploufragan-Plouzané-Niort (PPN) laboratory works more specifically on the health and welfare of production animals including pigs. Within the PPN Laboratory, the Swine Virology and Immunology Unit is interested in various viral infections, including African Swine Fever, for which it is National Reference Lab and as such develops reference and research activities, particularly in the field of vaccinology.

Sponsors

Contact

Marine Pentier

We are very honoured to count MSD among the Sponsors of BioFIT 2021

We are very honoured to count MSD among the Sponsors of BioFIT 2021

Many thanks to MSD for joining BioFIT 2021 as a Silver Sponsor

MSD has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs.  Our scientific advances have made a difference in the lives of millions of patients worldwide… and many of these advances were the result of partnerships.  In 2016, more than 60% of our human health sales were attributable to alliance partnerships and patents and we continue to work with our partners in some of the most challenging areas of biomedical research. With more than 100 business development transactions since 2015, our team has experience working on collaborations from discovery to clinical-stage programs regardless of therapeutic area or modality.  We believe that by working together we can play a major role in transforming global health care.  Together we can invent for life.

Join key BioFIT 2021 sponsors such as Boehringer Ingelheim, Genfit, MSD and Novo Nordisk to have the opportunity to:

  • Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
  • Highlight your interest in early-stage innovation
  • Present your ideas and technologies to key innovation players in Life Sciences
  • Enhance your visibility on an international scale and be recognised as a key innovative actor
  • Show your expertise thanks to specific communication tools

For more information about the sponsorship opportunities, visit the dedicated site page.

Sponsors

Contact

Marine Pentier

We are very honoured to count GENFIT among the Sponsors of BioFIT 2021

We are very honoured to count GENFIT among the Sponsors of BioFIT 2021

Many thanks to Genfit for joining BioFIT 2021 as a Bronze Sponsor

GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with cholestatic and metabolic chronic liver diseases. GENFIT is a pioneer in the field of nuclear receptor-based drug discovery, with a rich history and strong scientific heritage spanning more than two decades. GENFIT is currently enrolling in ELATIVE™, a Phase 3 clinical trial evaluating elafibranor* in patients with Primary Biliary Cholangitis (PBC). As part of GENFIT’s comprehensive approach to clinical management of patients with liver disease, the Company is also developing NIS4™, a new, non-invasive blood-based diagnostic technology which could enable easier identification of patients with at-risk NASH. NIS4™ technology has been licensed to LabCorp® in the U.S. and Canada for the development and commercialization of a blood-based molecular diagnostic test powered by NIS4™ technology. Nasdaq and Euronext: GNFT.
* Elafibranor is an investigational compound that has not been reviewed and has not received approval by any regulatory authority

Join key BioFIT 2021 sponsors such as Boehringer Ingelheim and Genfit to have the opportunity to:

  • Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
  • Highlight your interest in early-stage innovation
  • Present your ideas and technologies to key innovation players in Life Sciences
  • Enhance your visibility on an international scale and be recognised as a key innovative actor
  • Show your expertise thanks to specific communication tools

For more information about the sponsorship opportunities, visit the dedicated site page.

Sponsors

Contact

Marine Pentier

BioFIT 2021: new dates & format

BioFIT 2021: new dates & format


NEW DATES & FORMAT:
December 7th – 9th, 2021 | Digital event

Dear Community,

Guided by a concern for everyone’s health, BioFIT organisers and its Steering Committee have come to the conclusion that the best option for the upcoming edition of BioFIT was to move forward with a digital format and to extend it to 3 days.

The next edition of BioFIT, initially scheduled to take place in December 2021 in Strasbourg,will therefore be held ONLINE, from December 7th to 9th, 2021.

Given the evolution of the health situation, it seems safer to hold an international event like BioFIT in a 100% digital format this year again.
Indeed, while we are aware that we could expect a return to normal after the summer with vaccination, the uncertainties we are currently still facing regarding sanitary measures and international business travel for the end of the year significantly compromise a proper promotion for our event in a physical format.

Holding the next edition of BioFIT digitally, and announcing it now, will make it easier for our ecosystem to plan their participation in the event and ensure that a critical mass is reached for the 2021 edition.

We are convinced that holding the event in a digital format will be beneficial both in terms of quality and attendance.
Going online will allow us to fulfil our promise: to bring satisfaction to our participants and our partners in terms of meeting opportunities, deals achieved, partnerships launched…
Moreover, in order to enable more meeting opportunities and avoid “zoom-fatigue”, the duration of the event is extended to 3 days rather than 2.

Our choice has been to resort to a high-quality digital solution to offer you an optimal user experience. 
With the same top-notch one-on-one partnering meetings, valuable content and high-level experts, BioFIT Digital continues to safely offer you a unique experience, and to help you drive innovation forward in the sector.

The registration and exhibition fees to the event have been adjusted.

Register now and benefit from the Super Early Bird offer valid until April 29th, 2021!

You can count on our commitment to deliver the upcoming edition of BioFIT in the best conditions and to guide you through this digital configuration.
Please stay tuned for more information on the format, and do not hesitate to contact us if you have any questions.

We look forward to seeing you virtually in December!
Best regards,
The BioFIT team

Sponsors

Contact

Marine Pentier

We are very honoured to count Boehringer Ingelheim among the Sponsors of BioFIT 2021

We are very honoured to count Boehringer Ingelheim among the Sponsors of BioFIT 2021

Many thanks to Boehringer Ingelheim for joining BioFIT 2021 as a Bronze Sponsor

Boehringer Ingelheim is a global group of companies embracing many cultures and diverse societies. 

Improving the health and quality of life of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention. 

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of 17.5 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 18.1 per cent of net sales. 

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment. 

Join key BioFIT 2021 sponsors such as Boehringer Ingelheim and Genfit to have the opportunity to:

  • Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
  • Highlight your interest in early-stage innovation
  • Present your ideas and technologies to key innovation players in Life Sciences
  • Enhance your visibility on an international scale and be recognised as a key innovative actor
  • Show your expertise thanks to specific communication tools

For more information about the sponsorship opportunities, visit the dedicated site page.

Sponsors

Contact

Marine Pentier

The BioFIT 2021 brochure is available!

The BioFIT 2021 brochure is available!

Discover the BioFIT 2021 brand new brochure!

Download it to learn more about the 10th edition of BioFIT, the leading European partnering event for early-stage deals and investment rounds in the Life Sciences field!

Sponsors

Contact

Marine Pentier

Save the Date for BioFIT 2021

Save the Date for BioFIT 2021

A successful 2020 edition

For this 9th edition, BioFIT, the leading European partnering event for early-stage deals and investment rounds in the Life Sciences field, was organised for the first time in a digital format and was a real success.

This digital experience over 4 days has allowed participants to take away new ideas, new collaborations and new funding opportunities from their participation, all to build the innovations of tomorrow in the Life Science industry.

Over 1,000 attendees from over 36 countries have attended BioFIT/MedFIT Digital 2020. During the 4 day-event, 9,000 one-to-one meetings have been generated, 70 speakers have debated the right funding sources for early-stage innovation, the best practices in academia-industry R&D collaborations, and the winning ways to nurture emerging assets, 70 entities have increased their visibility through exhibition virtual stands, and 62 innovative projects previously selected have had the opportunity to pitch.

Save the date for the 10th edition

We hope to get the pleasure to welcome you to the next edition of BioFIT, in the charming city of Strasbourg, on December 14th and 15th, 2021. Looking forward to seeing you!

Register now and benefit from the Super Early Bird offer valid until March 31st, 2021!

Sponsors